Live prices from 19 SA suppliers, from R390.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Try removing a filter or two to widen the search.
Try removing a filter or two to widen the search.
More ways to compare SS-31
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Mitochondrial-Targeted Peptide | Cardiolipin Protector
SS-31 (Elamipretide) is an aromatic-cationic tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function for enhanced cellular energy production.
Selectively binds to cardiolipin in inner mitochondrial membrane, preventing lipid peroxidation and optimizing electron transport chain function. This improves ATP production and reduces oxidative damage at the mitochondrial level.
Optimizes electron transport chain function for improved cellular energy.
Prevents cardiolipin peroxidation and reduces mitochondrial oxidative damage.
Significant improvements in 6-minute walk test and fatigue scores in PMM patients.
Reduces cardiac injury markers and improves mitochondrial function in surgical patients.
Reduces ischemia-reperfusion injury and supports cardiac function.
Enhanced exercise capacity and reduced fatigue.
Reversed age-related decline in muscle function in animal studies.
Neuroprotective effects demonstrated in Alzheimer's models.
Supports overall cellular health through mitochondrial optimization.
Subcutaneous or intravenous injection. SS-31 dissolves readily and should be protected from light due to photosensitivity.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General mitochondrial support | 5-10mg | Once daily | SubQ |
| Athletic performance | 10-20mg | Once daily pre-workout | SubQ |
| Clinical protocols | 40mg | Once daily | SubQ or IV |
| Acute cardioprotection | 0.25mg/kg/hr | Continuous infusion | IV |
Topical cream/gel formulation available with limited research data. Used primarily for anti-aging skin applications.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Skin anti-aging | 0.5-1% cream/gel | Twice daily | Face, neck, hands |
Both support mitochondrial function through different mechanisms.
Both are mitochondrial peptides with complementary mechanisms.
May work together to protect cellular function.
Different mechanisms; no conflicts.
BPC-157 focuses on tissue repair while SS-31 targets cellular energetics.
Both cardioprotective via different pathways.
Subtle energy improvements, reduced fatigue
Better exercise endurance, faster recovery
Improved stamina, clearer thinking, better sleep
Significant exercise capacity improvements
Sustained energy, potential biomarker changes
Journal of Cardiac Failure
Potential cardioprotective effects in COVID-related cardiac injury.
Neurobiology of Aging
Demonstrated neuroprotective effects in Alzheimer's disease models.
Kidney International
Renal protective effects in acute kidney injury models.
40mg daily for 12 weeks in 36 patients showed significant improvements in 6-minute walk test and fatigue scores with excellent safety profile.
0.25mg/kg/hr infusion during cardiac surgery reduced cardiac injury markers and improved mitochondrial function.
8 weeks in aged mice reversed age-related decline in muscle function, increased ATP production, and reduced oxidative stress.
Phase 3 trial with 40mg daily for 48 weeks showed trends toward cardiac improvement in this rare mitochondrial disorder.
Plain-English guides and study summaries from published literature.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.
